EPS for Accenture plc (ACN) Expected At $1.71; Esperion Therapeutics, Inc. (ESPR) Had 10 Bulls

June 21, 2018 - By Michael Collier

Accenture plc (NYSE:ACN) Logo

Analysts expect Accenture plc (NYSE:ACN) to report $1.71 EPS on June, 28 before the open.They anticipate $0.19 EPS change or 12.50% from last quarter’s $1.52 EPS. ACN’s profit would be $1.10B giving it 23.65 P/E if the $1.71 EPS is correct. After having $1.58 EPS previously, Accenture plc’s analysts see 8.23% EPS growth. The stock decreased 0.94% or $1.54 during the last trading session, reaching $161.77. About 2.03 million shares traded. Accenture plc (NYSE:ACN) has risen 26.72% since June 21, 2017 and is uptrending. It has outperformed by 14.15% the S&P500. Some Historical ACN News: ; 22/03/2018 – ACCENTURE PLC – NOW EXPECTS OPERATING MARGIN FOR FULL FISCAL YEAR TO BE 14.8 PERCENT; 06/03/2018 – Accenture Invests in Leading Enterprise Augmented Reality Software Provider Upskill; 21/05/2018 – Accenture Again Named Technology Advisory House of the Year by Energy Risk Magazine; 22/03/2018 – Accenture’s revenue rises 15.2 percent; 22/03/2018 – Accenture Beats Profit And Revenue Expectations, Raises Outlook — MarketWatch; 22/03/2018 – Accenture Closes Below 50-Day Moving Average: Technicals; 29/03/2018 – Accenture To Acquire MXM, A Content-Powered Digital Marketing Agency; 23/05/2018 – Accenture Commits US$200 Million to Education, Training and Skills Initiatives Over Next Three Years to Equip Disadvantaged People for Work in the Digital Age; 22/03/2018 – ACCENTURE ACN.N SEES FY 2018 ADJUSTED SHR $6.61 TO $6.70; 09/05/2018 – Insurers Must Reskill and Reshape Their Workforces to Seize Growth Opportunities from Artificial Intelligence, According to

Among 19 analysts covering Esperion Therapeutics (NASDAQ:ESPR), 10 have Buy rating, 3 Sell and 6 Hold. Therefore 53% are positive. Esperion Therapeutics had 68 analyst reports since July 28, 2015 according to SRatingsIntel. Chardan Capital Markets maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) on Tuesday, September 29 with “Sell” rating. The rating was maintained by Cowen & Co on Wednesday, October 18 with “Buy”. Stifel Nicolaus maintained the shares of ESPR in report on Thursday, February 25 with “Buy” rating. The stock has “Buy” rating by Cowen & Co on Wednesday, March 7. The rating was maintained by Northland Capital with “Buy” on Wednesday, November 22. Barclays Capital downgraded the stock to “Equal-Weight” rating in Wednesday, June 29 report. JP Morgan downgraded the stock to “Neutral” rating in Wednesday, June 29 report. On Wednesday, February 21 the stock rating was maintained by Needham with “Buy”. As per Monday, March 19, the company rating was maintained by Jefferies. On Thursday, December 14 the stock rating was upgraded by Needham to “Buy”. See Esperion Therapeutics, Inc. (NASDAQ:ESPR) latest ratings:

04/05/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $108 New Target: $73 Maintain
03/05/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Old Target: $65 Downgrade
03/05/2018 Broker: J.P. Morgan Rating: Sell New Target: $41.0000 Downgrade
03/05/2018 Broker: Deutsche Bank Rating: Buy New Target: $75.0000 Maintain
02/05/2018 Broker: JMP Securities Rating: Buy New Target: $153.0000 Maintain
02/05/2018 Broker: Bank of America Old Rating: Buy New Rating: Underperform Downgrade
19/04/2018 Broker: Northland Capital Rating: Buy New Target: $121.0000 Maintain
27/03/2018 Broker: Cowen & Co Rating: Buy New Target: $95.0000 Maintain
27/03/2018 Broker: Chardan Capital Markets Old Rating: Neutral New Rating: Neutral Old Target: $75 New Target: $100 Maintain
19/03/2018 Broker: Jefferies Rating: Buy New Target: $85.0 Maintain

More notable recent Esperion Therapeutics, Inc. (NASDAQ:ESPR) news were published by: Seekingalpha.com which released: “Esperion Therapeutics halted pending news” on May 23, 2018, also Nasdaq.com with their article: “Esperion Announces Late-Breaking Oral Presentation of Full Study 4 Results (1002-048) at the International …” published on June 12, 2018, Nasdaq.com published: “New Research Coverage Highlights Esperion Therapeutics, Magna International, Spectra Energy Partners, LP, Toronto …” on June 01, 2018. More interesting news about Esperion Therapeutics, Inc. (NASDAQ:ESPR) were released by: Nasdaq.com and their article: “Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” published on May 25, 2018 as well as Nasdaq.com‘s news article titled: “Esperion Announces the Appointment of Jay P. Shepard to Board of Directors” with publication date: May 29, 2018.

The stock increased 1.62% or $0.67 during the last trading session, reaching $42. About 677,588 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 12.80% since June 21, 2017 and is uptrending. It has outperformed by 0.23% the S&P500. Some Historical ESPR News: ; 10/05/2018 – Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2018 Healthcare Conference; 27/03/2018 – Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor in Patients wit; 15/05/2018 – The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Esperion; 07/03/2018 – Esperion: 12-week Study Met Its Primary Endpoint With LDL-C Lowering Totaling 28 %; 07/03/2018 – #2 Flanked by rivals and skeptics, Esperion flips positive data on first PhIII for a potentially game-changing cholesterol pill $ESPR; 07/03/2018 – ESPERION SHARE RISE 7.8% AFTER HEART PILL RESULTS; 07/03/2018 – Esperion to Participate in Fireside Chat at March 2018 Investor Conferences; 02/05/2018 – Esperion Therapeutics Cash and Cash Equivalents and Investment Securities Available-For-Sale Totaled $239.6M at March 31; 22/05/2018 – Kessler Topaz Meltzer & Check, LLP Announces Investor Class Action Lawsuit Filed Against Esperion Therapeutics, Inc; 14/05/2018 – DEADLINE ALERT: Shareholder Class Action Lawsuit Filed Against Esperion Therapeutics, Inc. — ESPR

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol . The company has market cap of $1.13 billion. The Company’s lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. It currently has negative earnings.

Investors sentiment increased to 1.5 in 2018 Q1. Its up 0.17, from 1.33 in 2017Q4. It is positive, as 14 investors sold Esperion Therapeutics, Inc. shares while 46 reduced holdings. 36 funds opened positions while 54 raised stakes. 24.56 million shares or 8.25% more from 22.69 million shares in 2017Q4 were reported. Services Automobile Association accumulated 0% or 3,390 shares. Rhumbline Advisers, Massachusetts-based fund reported 17,194 shares. Hamilton Lane Advsr Ltd Company reported 31,562 shares. Blackrock holds 0.01% in Esperion Therapeutics, Inc. (NASDAQ:ESPR) or 1.49M shares. Wasatch Advisors Incorporated reported 0.55% stake. Retail Bank Of America De accumulated 0% or 47,875 shares. State Street accumulated 0.01% or 1.31M shares. Tekla Cap Mngmt Ltd accumulated 189,287 shares or 0.53% of the stock. Atlantic Trust Gp Ltd Company stated it has 1,000 shares or 0% of all its holdings. Point72 Asia (Hong Kong) Ltd holds 664 shares or 0.02% of its portfolio. Ameriprise Fincl holds 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR) or 21,472 shares. Stifel has 12,441 shares. Tiverton Asset Mgmt Ltd Liability Corporation, a Delaware-based fund reported 34,180 shares. Geode Capital Management Ltd Liability holds 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR) for 178,743 shares. The New York-based Lazard Asset Management Limited Liability Corporation has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR).

Among 26 analysts covering Accenture Plc (NYSE:ACN), 16 have Buy rating, 1 Sell and 9 Hold. Therefore 62% are positive. Accenture Plc has $181 highest and $11 lowest target. $151.54’s average target is -6.32% below currents $161.77 stock price. Accenture Plc had 98 analyst reports since August 12, 2015 according to SRatingsIntel. The stock has “Buy” rating by Cowen & Co on Monday, October 23. On Thursday, December 21 the stock rating was maintained by RBC Capital Markets with “Buy”. BMO Capital Markets maintained it with “Hold” rating and $15800 target in Thursday, March 22 report. The firm earned “Buy” rating on Sunday, October 29 by KeyBanc Capital Markets. Morgan Stanley upgraded the shares of ACN in report on Monday, February 5 to “Buy” rating. On Monday, August 14 the stock rating was maintained by RBC Capital Markets with “Buy”. The firm has “Hold” rating by Credit Suisse given on Monday, March 27. The stock of Accenture plc (NYSE:ACN) has “Hold” rating given on Wednesday, December 27 by Robert W. Baird. The firm earned “Hold” rating on Friday, March 24 by BMO Capital Markets. The rating was maintained by Barclays Capital on Friday, September 30 with “Equal-Weight”.

Another recent and important Accenture plc (NYSE:ACN) news was published by Fool.com which published an article titled: “What’s Accenture’s Secret Sauce?” on June 09, 2018.

Investors sentiment increased to 0.97 in 2018 Q1. Its up 0.04, from 0.93 in 2017Q4. It improved, as 50 investors sold Accenture plc shares while 396 reduced holdings. 105 funds opened positions while 326 raised stakes. 449.75 million shares or 1.56% less from 456.89 million shares in 2017Q4 were reported. Trust Company Of Toledo Na Oh reported 3,021 shares. Raub Brock Capital L P reported 124,508 shares. Security Trust reported 858 shares. Everett Harris Ca reported 266,631 shares. Lombard Odier Asset Mngmt (Switzerland) owns 3,925 shares. Dimensional Fund Ltd Partnership has invested 0.11% in Accenture plc (NYSE:ACN). The New York-based M&R Cap Mgmt has invested 1.94% in Accenture plc (NYSE:ACN). Cetera Advisor Networks Limited Liability Co holds 0.03% of its portfolio in Accenture plc (NYSE:ACN) for 4,720 shares. Zacks Invest Mgmt reported 0.26% in Accenture plc (NYSE:ACN). Schwerin Boyle Cap owns 254,195 shares or 4.28% of their US portfolio. Zeke Cap Limited Liability stated it has 15,385 shares or 0.22% of all its holdings. Weatherly Asset Management Limited Partnership reported 0.29% stake. Hilton Cap Mgmt Limited Liability Corporation has 0.03% invested in Accenture plc (NYSE:ACN). Provident Tru, a Wisconsin-based fund reported 1.17 million shares. Arete Wealth Advsr Ltd has 0.11% invested in Accenture plc (NYSE:ACN) for 2,207 shares.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Michael Collier

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: